Activation of ABCA7 expression levels using the taRNAs described here offers a possible strategy to both probe the therapeutic potential of ABCA7 activation in animal models of AD, as well as to provide a starting point for therapeutic development. This evidence concerns the gene ABCA7 and Alzheimer disease.